Trump’s Mysterious Obesity Drug Use Sparks Speculation
A 79-year-old patient has received early access to Eli Lilly’s experimental obesity drug, retatrutide, via the FDA’s “compassionate use” program. This highly anticipated drug targets multiple hormones for weight loss and is currently in late-stage trials. The request was made by an NIH clinician for a patient with severe obesity and related conditions who had limited success with another GLP-1 and GIP targeting drug and was deemed ineligible for bariatric surgery. The unique circumstances of this sole approval have sparked speculation, with reports suggesting the patient may be President Donald Trump.
John Q. Hosedrinker